Genelux CORP
Forward trial catalysts linked to GNLX
CSA tracks 1 forward catalyst for Genelux CORP across 1 asset, spanning Phase 3. The nearest is a readout expected Dec 2026 (month precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Platinum-resistant Ovarian Cancer.
GNLX in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Genelux CORP has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
1 trial behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| olvimulogene nanivacirepvec | NCT05281471 catalyst | Phase 3 | Recruiting | 2026-12 | Experimental | Genelux Corporation | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Canc… |
Every trial the CSA sample links to GNLX's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →